Introduction
Targeting the epidermal growth factor receptor (EGFR) using tyrosine kinase inhibitors (TKIs) has proven to be an effective treatment strategy for advanced non-smallcell lung cancer (NSCLC). However, not all patients benefit from TKI treatment, and several investigators have sought to identify a priori markers that will predict a response to, and benefit from treatment. Certain clinical characteristics have been shown to be associated with an increased likelihood of responsiveness to EGFR TKIs (female gender, nonsmoking history, adenocarcinoma histology and East Asian race) . In addition, several molecular predictors are associated with responsiveness to EGFR TKI treatment, and seem to be more reliable predictors of response than clinical features. This review discusses candidate molecular predictive markers of anti-EGFR therapy and the different methodologies used to assess them.
Molecular predictors of response to EGFR antagonists
Protein expression by immunohistochemistry There are several ways to detect EGFR protein and measure its levels. These include radioactive-labeled ligand binding, competitive immunoassay, western blotting and immunohistochemistry. The first three methods require protein extraction from fresh or snap-frozen samples. Although these methods are quantitative, they require special laboratory setups that are more suitable for basic research. In addition, as protein is extracted from whole tissue, normalization of results for tumor cell content can be problematic. Immunohistochemistry has several advantages over the above assays: (1) protein expression level can be evaluated directly on tumor cells or on other specific cells of interest; (2) the technique can be performed on formalin-fixed, paraffin-embedded (FFPE) tumor tissues, which represent the largest archival bank of human tissue samples; and (3) immunohistochemistry is a technique that is routinely used in clinical pathology practice. Countering these advantages, however, is the fact that quantification of expression levels by visual inspection can be regarded as semiquantitative at best and a challenge to standardize.
Most laboratories use the indirect immunolabeling method for immunohistochemistry. The factors that are most likely to influence immunoreactivity and staining include types of tissue fixative and condition of fixation, as well as the reactivity and specificity of the primary antibody (Atkins et al., 2004; Dei Tos and Ellis, 2005; Penault-Llorca et al., 2006; Buckley and Kakar, 2007) . Several commercial antibodies for EGFR are available. The two most commonly used are the DakoCytomation (Carpentaria, CA, USA) clone 18C9, which is used in the pharmDx kit, and the Zymed Laboratories Inc. (South San Francisco, CA, USA) clone 31G7 (Bhargava et al., 2006; Penault-Llorca et al., 2006) . To obtain consistent results, immunohistochemistry studies require carefully controlled and validated standard operating procedures.
Immunohistochemistry results can be evaluated qualitatively for the absence or presence of staining of the studied cells, and semiquantitatively for the intensity of staining, percentage of stained cells or both. In addition, by multiplying the staining intensity by the percentage of cells stained, an H-score can be derived. A simple H-score may be based on a single predominant staining intensity, whereas more complex H-scores can include the sum of individual H-scores for each intensity level observed. The sample can then be scored as positive or negative on the basis of specific adopted cutoff points. The method for determining such a cutoff is one of the controversial issues in immunohistochemistry scoring.
EGFR immunohistochemistry as a prognostic and predictive biomarker Studies using different antibody sources have reported a high prevalence of EGFR immunostaining in NSCLCs (Rusch et al., 1997; Fontanini et al., 1998; Hsieh et al., 2000; Hirsch et al., 2003) . The rate is consistently higher in squamous-cell carcinomas (55-100%) than in adenocarcinomas (35-60%) or large-cell carcinomas (20-60%). Several studies have shown an association between EGFR protein expression and response to EGFR TKIs; however, there have been conflicting results with regard to the value of EGFR protein expression in predicting survival benefit with EGFR TKIs (see Hirsh et al., 2009) .
EGFR immunohistochemistry as a clinical test
Several major issues with technical aspects of immunohistochemistry require standardization, although the most important variables include the type and source of antibody and the scoring system used (Dei Tos and Ellis, 2005; Eberhard et al., 2008; Hirsch et al., 2008a) . Discordance between antibodies may be significant, ranging from 12 to 24% (Buckley and Kakar, 2007; Hirsch et al., 2008a) . EGFR immunohistochemistry is therefore not yet optimal in determining a patient's eligibility to receive EGFR TKI therapy (Ciardiello and Tortora, 2008) , despite results indicating that EGFR immunohistochemistry-negative patients demonstrate reduced responses and clinical benefit.
EGFR gene copy or dosage
The EGFR gene is located on the short arm of chromosome 7 (7p21), which is commonly overrepresented or amplified in NSCLC. There are several methods for detecting and determining EGFR gene copy number and dosage, including fluorescence in situ hybridization (FISH), chromogenic in situ hybridization (CISH) and real-time quantitative polymerase chain reaction (qPCR).
FISH
The development of fluorescent-labeling techniques has enabled multiple targets on the same or separate chromosomes to be analysed simultaneously, thereby allowing control probes to be hybridized and used as a reference (Trask et al., 1985) . This involves labeling the DNA fragment of a gene, or the bacterial artificial chromosome corresponding to the gene, with a specific fluorescent dye. As multiple fragments can be labeled using fluorophores with different emission wavelengths, multiple FISH probes can be co-hybridized to detect different genes in a single assay. The fluorescent labels enable the visualization of the number of copies and location of the target genes in metaphase as well as interphase nuclei. The technique for the EGFR FISH assay is well described (Varella-Garcia, 2006) and performed routinely using B4-mm-thick FFPE tissue sections. The most commonly used probe is the LSI EGFR SpectrumOrange/CEP 7 SpectrumGreen probe set (Vysis Inc., Downers Grove, IL, USA). This probe set includes directly labeled DNA FISH probes for the EGFR gene and the centromere of chromosome 7. There are several technical considerations that could compromise the FISH assay, including lengths of proteinase K digestion and probe hybridization duration and condition (Varella-Garcia, 2006) .
The currently used EGFR FISH scoring system was developed by the Colorado group (Cappuzzo et al., 2005) and requires the use of an epifluorescence microscope equipped with a genetic workstation. The cutoffs used for this scoring system were determined in a retrospective study of gefitinib-treated patients with advanced NSCLC (Cappuzzo et al., 2005) . Unlike the FISH assay for the HER2 gene in breast cancer, the scoring system for the EGFR gene copy changes in NSCLC is more complex, perhaps reflecting the different biological impact of the two genes in the two diseases. The system stratifies tumors into six categories on the basis of the quantity of tumor cells with a specific EGFR gene copy number compared with the chromosome 7 copy number, which is scored using the CEP7 probe. Tumors are considered FISH positive if they show amplification (the presence of tight gene clusters and a ratio of X2 genes/chromosomes per cell or X15 gene copies per cell in X10% of analysed cells) or high polysomy (X4 copies of the gene in X40% of cells). Tumors considered FISH negative are those with no amplification as defined above or with o40% of cells showing X4 copies of the EGFR gene per cell (VarellaGarcia, 2006) .
EGFR FISH as a prognostic and predictive biomarker
The association between the high EGFR gene copy by FISH (FISH-positive), as defined by the Colorado group (Cappuzzo et al., 2005) , and the clinical end points of EGFR TKI therapies has been investigated in a number of studies. In the Italian Expanded Access Study of gefitinib, the BR.21 and the ISEL studies, an association was observed between EGFR FISH positivity and either increased response rates or an improved survival benefit (Hirsch et al., 2003 (Hirsch et al., , 2006 Tsao et al., 2005; see Hirsch et al., 2009) . The high EGFR gene copy number detected by FISH may also be predictive of benefit from chemotherapy combined with cetuximab (Hirsch et al., 2008b) .
Compared with reports in Caucasian patients, only a limited number of FISH studies have been conducted in East Asian patients with NSCLC treated with EGFR TKIs (Ichihara et al., 2007; Sone et al., 2007) . In the studies by Ichihara et al. (2007) and Sone et al. (2007) , 41% of patients were FISH positive, but FISH positivity was not associated with survival benefit, suggesting a discrepancy between East Asian and Caucasian ethnicities. It is hoped that the FISH analysis from the recently presented I-PASS study will further clarify this issue (Mok et al., 2008) .
CISH
CISH is an alternative assay to FISH for determining gene copy number and amplification in tissue sections. The major difference between the two methods is that FISH requires an epifluorescent system, whereas CISH can be evaluated by the pathologist using bright-field microscopy and correlated directly with histopathology. Furthermore, as with immunohistochemistry, CISHstained slides can be archived and stored permanently.
The DNA probes are labeled with digoxigenin or biotin (Gallegos Ruiz et al., 2007; Sholl et al., 2007; Chang et al., 2008; Li et al., 2008) and then detected using a CISH Detection Kit (Zymed Laboratories, South San Francisco, CA, USA). Gene/chromosome probes are visualized as dark brown dots, which are counted in parallel sections using standard light microscopy and are converted into the number of nuclear signals per cell. CISH may be useful in samples that are difficult to interpret by fluorescence microscopy because of sample heterogeneity, high autofluorescent background signal or both (Daniele et al., 2007) . The main potential drawback of CISH compared with FISH is that most CISH studies have been performed on frozen sections and only a single color can be developed per section, meaning that one is not able to evaluate a control probe for aneusomy. Therefore, the complex scoring system proposed for FISH (Cappuzzo et al., 2005) may not be extrapolated automatically to CISH. Nevertheless, with a scoring system that depends only on an EGFR gene signal, CISH is an alternative method for assessing EGFR gene copy status.
In a recent study comparing the performance of FISH and CISH for the detection of increased EGFR copy number in 77 patients with NSCLC treated by surgery alone (Figure 1 ), a significant correlation was found between the number of signals detected by both methods (Spearman's r ¼ 0.81; Po0.0001) (Sholl et al., 2007) . Discrepancies between the two tests were seen in only 7% of cases. At a signal of 4.5, CISH had very high sensitivity (89%) and specificity (89%) for the discrimination of low and high EGFR polysomy (Po0.0001). At a signal of 7.1, CISH was also effective at distinguishing between high polysomy and amplification (P ¼ 0.0003). Another study comparing CISH and FISH in 58 NSCLC samples showed similar results, with a high concordance between EGFR copy number determined by the two tests (Gallegos Ruiz et al., 2007) . Overall, these data support the feasibility of using CISH to evaluate the function of EGFR gene copy as a predictive marker for EGFR TKI therapy, although further evaluation and validation in clinical trial samples is needed before this technique can be adopted clinically.
qPCR Several different methods of performing qPCR measurements can be used to detect small amounts of RNA or DNA (Bustin, 2002) . Using probes that are labeled with both a fluorophore and fluorescence-quenching molecule, amplicon generation can be detected and quantified in real time during a PCR. An alternative and less expensive method uses the double-stranded DNA intercalating agent, SYBR Green, as the signal emitter. Using multiple primers labeled with different fluorophores, current qPCR technology can quantitate multiple genes, including control genes, simultaneously in one reaction.
The greatest pitfall for using qPCR to measure gene dosage is the inability to control for contamination from normal host cells that result in the dilution of tumor cell gene copy. Performing laser-capture microdissection can reduce this problem, but this is laborious and clinically impractical. The other issue with qPCR-based gene dosage estimation is normalization. Normalization using another region of the same chromosome as the studied gene, such as centromeric sequences, will detect true amplification, but will not detect increased gene copy number due to polysomy. Normalization using centromeric sequences of multiple chromosomes may allow the assessment of the degree of aneusomy.
There have been two studies on EGFR gene dosage by qPCR to predict treatment benefit in patients with NSCLC receiving TKI therapy. Both studies failed to demonstrate its clinical applicability (Bell et al., 2005; Dziadziuszko et al., 2006) . EGFR qPCR was not predictive of response to treatment, disease control, progression-free survival or overall survival, nor did it correlate with FISH, immunohistochemistry or mRNA expression (Bell et al., 2005; Takano et al., 2005; Dziadziuszko et al., 2006 Dziadziuszko et al., , 2007 .
Somatic EGFR gene mutations
In May 2004, two independent groups of investigators reported the discovery of somatic mutations in the TK domain (exons 18-23) of EGFR (Lynch et al., 2004; Paez et al., 2004) . Practically all mutations that have been reported are on exons 18 through 21. These mutations affect the adenosine triphosphate (ATP)-binding cleft of EGFR, which is also where TKIs bind. In vitro studies have shown that EGFR mutants have constitutive TK activity and, therefore, a greater sensitivity to anti-EGFR inhibition. Among all mutations, four predominantly result in TKI drug sensitivity by in vitro and in vivo studies. These include point mutations in exons 18 (G719A/C) and 21 (L858R and L861Q) and in-frame deletions in exon 19, which eliminate four amino acids (LREA) downstream of the lysine residue at position 745; other mutations appear to be associated with variable or less sensitivity (Eberhard et al., 2005; Chen et al., 2006; Sharma et al., 2007; see Gazdar, 2009 ).
The most commonly used method to detect mutations is direct sequencing of the PCR-amplified exon sequences. Tumor sections are initially stained with hematoxylin and eosin (H&E) or methylene blue to determine tumor cell percentage and to account for all cellular components present. For the direct sequencing method, samples with tumor cellularity o40% should be enriched by microdissection. DNA is extracted from the selected tumor tissue using standard methods or a commercially available kit. After PCR amplification of each exon of the EGFR TK domain, amplicons are sequenced. The copy number of mutant allele, imbalanced PCR amplification and the relative amount of contaminating wild-type allele of non-tumor cells can influence the sensitivity of mutant detection by direct sequencing (Engelman et al., 2006) . In addition, DNA extracted from FFPE tissues could give rise to sequencing artifacts, thus requiring a confirmation by the sequencing of independent PCR products.
Owing to concern regarding the sensitivity of the direct-sequencing method, a variety of other methods have been investigated to detect low abundance mutations and increase the sensitivity of the mutation assay. These include high-resolution melting analysis (Nomoto et al., 2006; Willmore-Payne et al., 2006; Fukui et al., 2008) , single-stranded conformational polymorphism and denaturing high-performance liquid chromatography analysis of PCR amplicons after digestion by CEL1 endonuclease (Ja¨nne et al., 2006) . These methods allow the rapid mutation screening of large numbers of samples with increased sensitivity but still require direct sequencing to identify or confirm mutations. The amplification refractory mutation system (ARMS) (Newton et al., 1989; Whitcombe et al., 1999) , combined with the scorpion method (Kimura et al., 2006) and the peptide nucleic acid-locked clamping method (Nagai et al., 2005) , are alternative sensitive methods that may be used to detect rapidly specific EGFR mutations using real-time PCR-based technology.
EGFR mutations as biomarkers
Exon 19 deletion and exon 21 L858R substitution account for 85-90% of the drug-sensitive EGFR mutations seen in NSCLC (Riely et al., 2006; Sakurada et al., 2006) . The mutations are more common in adenocarcinomas, in persons of East Asian ethnicity, women and in never smokers. These phenotypic features had already been marked as clinical predictors of response to TKIs before the discovery of the mutations (Fukuoka et al., 2003; Kris et al., 2003) . The prevalence of EGFR mutations varies by ethnicity with ranges from 20-40% in Asian populations (Huang et al., 2004; Kosaka et al., 2004; Han et al., 2005; Shigematsu et al., 2005; Tokumo et al., 2005) to 5-20% among Caucasians (Cappuzzo et al., 2005; Marchetti et al., 2005) .
The association between the presence of activating EGFR mutations and high response rates to TKIs was demonstrated in a number of phase II studies in which all patients received EGFR TKI therapy. The overall response rates were as high as 80% in patients harboring mutations compared with p10% in patients with wildtype EGFR (Huang et al., 2004; Lynch et al., 2004; Mu et al., 2004; Paez et al., 2004; Pao et al., 2004; Sasaki et al., 2006; Kosaka et al., 2007; Yoshida et al., 2007; see Gazdar, 2009) .
Mutations in the kinase domain of EGFR have also been associated with an acquired resistance to EGFR TKIs. A secondary mutation involving the substitution of methionine for threonine in codon 790 (T790M) is present in approximately 50% of cases of acquired resistance (Kobayashi et al., 2005; Pao et al., 2005a; Kosaka et al., 2006; see Gazdar, 2009) . Screening for the emergence of the T790M mutation during treatment may allow for the earlier identification of acquired resistance. A recent study showed that T790M can be detected before EGFR TKI treatment with a highly sensitive allele-specific assay (Maheswaran et al., 2008) . The investigators found that the pretreatment presence of T790M did not preclude responses with EGFR TKIs, but was associated with significantly shorter progression-free survival compared with patients without detectable T790M before TKI treatment (7.7 vs 16.5 months; Po0.001). These results suggest that T790M may be a useful pretreatment biomarker for identifying patients who are not likely to experience long-term benefits with reversible EGFR TKIs (that is, erlotinib and gefitinib).
Genetic polymorphisms and EGFR-targeted drugs
The EGFR gene contains numerous genetic polymorphic variants. The evaluation of germ line genetic variants uses DNA extracted from any non-tumor source, including leukocytes from whole blood. Several genetic variants are associated with alterations in the mRNA gene expression (Liu et al., 2005) . Both the EGFR -216G/T and -191C/A polymorphisms are located in the transcriptional start site region of the promoter, wherein multiple nuclear regulatory affinity sites are located (Liu et al., 2005) . Two studies in Caucasian patients reported that the -216G/T variant, alone or in combination with -191C/A, was associated with improved outcome, greater toxicity to gefitinib or both (Cusatis et al., 2006; Liu et al., 2008) , whereas a third found no association (Gregorc et al., 2008) . Among Asians, these variants are rare (Ichihara et al., 2007) .
One of the enhancer elements for EGFR is located in intron 1 (Maekawa et al., 1989; Haley and Waterfield, 1991) . Shorter alleles of the dinucleotide CA repeat sequence polymorphism in intron 1 of EGFR are associated with a greater EGFR expression than are the longer repeats (Gebhardt et al., 1999; EtienneGrimaldi et al., 2005) . In Asian patients, a shorter CA repeat length was associated with a greater EGFR expression and copy number (Zhou et al., 2006) . Asian patients tend to have longer CA repeat lengths. Two Asian studies (Han et al., 2007; Nie et al., 2007) and one American study found associations with lung cancer survival or toxicity with gefitinib, whereas others found no significant association (Ichihara et al., 2007; Gregorc et al., 2008) . Shorter CA repeat lengths were associated with poorer survival in the absence of therapy with an EGFR TKI, which is a reversal of expectations in TKI-treated patients (Dubey et al., 2006) . The multidrug transporter ABCG2 was shown to be active in removing gefitinib from cells (Elkind et al., 2005) . In published reports, ABCG2 polymorphisms have been identified as being associated with increased EGFR TKI concentrations, toxicity or both, in patients treated with gefitinib and erlotinib (Cusatis et al., 2006; Li et al., 2007; Rudin et al., 2008) .
In summary, genetic polymorphisms may be important contributors to variability in response to EGFR TKI therapy, but evidence is thus far contradictory. Several reasons exist to explain the inconsistent data:
(1) studies have been underpowered, with sample sizes generally lower than 200 patients; (2) different definitions are used for key variables, such as 'short' and 'long' intron 1 CA repeat lengths and 'clinical toxicity'; (3) confounders such as race, polymorphism allele frequencies, mutation rates, copy number changes and other clinical and molecular prognostic and predictive factors have rarely been accounted for in these polymorphism analyses. Comprehensive analyses are needed to determine whether genetic polymorphisms are independently predictive with EGFR TKI therapy, are simply correlated with other molecular or clinical prognostic factors, or are prognostic but not predictive.
KRAS gene mutation RAS is considered a 'master switch' signal transduction protein downstream of multiple types of cell surface receptors, including tyrosine kinase and G-proteincoupled receptors (Aviel-Ronen et al., 2006; Molina and Adjei, 2006) . A point mutation on codons 12, 13 and 61 of all RAS family genes will lead to the inability of the RAS-guanosine triphosphatase (RAS-GTPase)-activating protein to hydrolyse bound GTP to guanosine diphosphate, thus resulting in a constitutive activation of the RAS protein. In NSCLC, >90% of RAS mutations involve the KRAS gene, with most occurring in codon 12. The most direct way to detect KRAS codon 12 and 13 mutations is by PCR amplification of exon 2 and by direct sequencing of the amplicon. However, all the previously discussed caveats for the detection of EGFR mutations using this technique on FFPE samples apply, especially the need to enrich samples to X50% tumor cellularity. The need for repeat PCR to confirm mutations is less of a concern, as any mutations detected outside codons 12, 13 and 61 can be ignored. Pao et al. (2005b) first suggested that patients with NSCLC whose tumors harbor mutations are resistant to EGFR TKI. To date, among 75 NSCLC patients harboring KRAS mutations who were treated with TKIs (Pao et al., 2005b; Hirsch et al., 2006; Massarelli et al., 2007; Miller et al., 2008; Zhu et al., 2008) , only one patient has been reported to respond (Zhu et al., 2008) . Interestingly, this patient's tumor also had an EGFR gene amplification. On the basis of TKI response rates of up to 10% in patients with wild-type EGFR, one would expect that at least seven to eight of these 75 patients should have responded, suggesting that mutated KRAS results in TKI resistance. In the TRIBUTE study, patients with KRAS mutant tumors, who were treated with a combination of erlotinib and chemotherapy, showed poorer survival than did patients treated with chemotherapy alone or patients with wild-type KRAS, regardless of treatment type (Eberhard et al., 2005) . In the BR.21 study, KRAS mutations were found in 30 (15%) of 206 patients tested. The HR of erlotinib to placebo treatment in 30 patients with a KRAS mutation was 1.67 (95% CI, 0.62-4.50; P ¼ 0.31), whereas for 176 patients with wild-type KRAS it was 0.69 (95% CI, 0.49-0.97; P ¼ 0.03), with an insignificant interaction P-value of 0.09. In a multivariate analysis, KRAS mutation was neither prognostic for poorer survival in untreated patients nor predictive of differential treatment effect (Zhu et al., 2008) . Overall, these results suggest that patients with NSCLC who have KRAS mutations are unlikely to derive any benefit from current TKI therapy, although the number of reported cases remains limited.
MET amplification
Using gefitinib-resistant NSCLC cell lines, Engelman et al. (2007) recently found that amplification of the MET proto-oncogene may be involved in resistance to EGFR TKIs by enabling cells to activate the PI3K and Akt-signaling pathway independently of EGFR through HER3 activation. MET is commonly overexpressed in NSCLC (Tsao et al., 1998; Ma et al., 2005) and may be a poor prognostic marker (Cheng et al., 2005; Rossi et al., 2005) . It has been speculated that MET amplification accounts for approximately 10-20% of acquired resistance to gefitinib and erlotinib (Engelman and Ja¨nne, 2008) . In addition, preclinical data suggest that inhibition of MET can restore sensitivity to gefitinib (Engelman et al., 2007) . Although this requires further elucidation in a clinical setting, the dual inhibition of EGFR and MET may be an approach to overcome resistance to EGFR TKIs.
MET amplification can be detected either by qPCR or FISH (Engelman et al., 2007) . Along with the general challenges that accompany these two techniques, an added difficulty centers on the threshold level of MET amplification, which is clinically relevant for EGFR TKI treatment. Currently, this is not well defined and will clearly be important if this molecular factor is to be used as a biomarker for EGFR TKI treatment.
Practical considerations
EGFR TKIs are associated with significant clinical responses in 10-20% of Caucasian patients with heavily pretreated metastatic NSCLC and in 40-50% of East Asian patients. The ability to predict significant clinical benefits with appropriate biomarkers would be a major advancement in the achievement of personalized medicine for patients with NSCLC, as it would allow the tailoring of treatment with TKIs to patients who are most likely to benefit, whereas other patients would receive alternative therapies that may also be effective. To date, several such biomarkers and various technologies to assay them have been described and studied, but none is currently ready for clinical implementation. This is largely because of the fact that most biomarker study results have been derived from phase II trials in which all patients were treated, whereas very limited data are available from the results of phase III trials that included both drug-treated and placebo-controlled patients. The latter is important when one is trying to identify significant predictive markers that truly demonstrate differential benefits of therapies between markernegative and marker-positive patients .
To maximize the therapeutic index and cost-effectiveness of anti-EGFR therapy, both negative and positive predictive biomarkers should be considered. For negative markers that may potentially exclude patients from receiving therapy, the candidate markers are EGFR immunohistochemical negativity, KRAS mutation and MET amplification. Each of these has its respective shortcomings. For immunohistochemistry, a standardized assay and quantitative scoring procedures need to be established and validated prospectively. Despite accumulating evidence for KRAS tumors being resistant to EGFR TKIs, the number of reported cases remains low (o100 cases), especially considering that only 10% of tumors that are negative for both KRAS and EGFR mutations still respond to TKIs.
Both EGFR mutation and a high gene copy number (FISH positivity) are promising positive selection biomarkers (that is, markers to select patients who are likely to respond to TKI therapy). The current adoption of EGFR mutation as a selection marker would exclude EGFR TKI therapy in 80-90% of non-East Asian patients, whereas 50-60% would be excluded when using EGFR gene copy (FISH positivity) as a marker. However, the value of mutational analysis for predicting response may not be uniform across various ethnicities. For example, in Caucasian patients, whose overall response rate is 10%, it seems highly sensible to use mutational status as a marker to select the 10-20% of patients who are most likely to benefit from anti-EGFR therapy. Yet, many studies have consistently reported 10% response rates to gefitinib and erlotinib in patients with wild-type EGFR, and the HR of erlotinib to placebo is 0.74 (Zhu et al., 2008) , which is comparable to the overall survival benefit of erlotinib in all BR.21 patients (Shepherd et al., 2005) . Therefore, it may be that one unifying predictive model does not apply to all patients with NSCLC, and that it is more practical to define different models for patients of various ethnicities.
Finally, the adoption of biomarker analysis into clinical practice would be significantly facilitated if such tests could be performed using blood samples, especially considering the fact that for patients with advanced disease, the diagnosis is often made on fine-needle aspirates, which are not likely to yield adequate material for mutational/FISH testing. Kimura et al. (2006 Kimura et al. ( , 2007 reported the ability to detect EGFR mutations in serum samples of patients with advanced NSCLC with approximately 75% sensitivity. More recently, Maheswaran et al. (2008) reported 92% sensitivity in the detection of EGFR mutations in isolated circulating tumor cells, including the detection of the T790M-resistant mutants in patients undergoing TKI therapy. These approaches are becoming more feasible with the increasing availability of automated equipment necessary for the isolation of circulating tumor cells and may circumvent the issue of limited tissue availability.
The ability to personalize small molecule-based therapies on the basis of molecular markers remains elusive in patients with NSCLC, although enormous progress has been made in a relatively short period of time. The most appropriate biomarkers for predicting response and the preferred gene-sequencing technology for the determination of mutational status in routine clinical practice are important issues that need to be addressed. This can be achieved only by dedicated tumor banking and further molecular profiling of the tumors from patients enrolled in large phase III randomized studies.
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